Study examines trends in GLP-1RA prescriptions for type 2 diabetes and obesity in the US from 2011 to 2023.
- Nationwide study conducted to identify trends in the use of GLP-1RA medications like Ozempic and Wegovy in the U.S.
- GLP-1RA medications initially developed for type 2 diabetes, now approved for chronic weight management in adults with obesity.
- Significant surge in GLP-1RA prescriptions for weight loss management causing issues like drug shortage and accessibility problems.
- Data from the study shows a noticeable shift in GLP-1RA prescriptions towards treating obesity, with a decrease in prescriptions for type 2 diabetes.
- Researchers emphasize the need for careful monitoring of prescription patterns and ensuring equitable access to these essential treatments.
Source link
Diabetes & Endocrinology, Obesity, GLP-1RA, Prescriptions, Complications